Ελληνικά Πεπτίδια

Οι μελέτες

Κάθε ποσοστό σε αυτό το σάιτ βγαίνει από μία από αυτές. 30 δημοσιευμένες μελέτες, όλες με DOI — πάτα το και ανοίγει το πρωτότυπο. Δεν χρειάζεται να μας πιστέψεις.

Retatrutide

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
  2. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2

Semaglutide

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

Cagrilintide

  1. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081
  2. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7

Mazdutide

  1. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). N Engl J Med. 2025;392(22):2215-2225. doi:10.1056/NEJMoa2411528
  2. Xie Z, Zheng G, Liang Z, et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis. Metabolism. 2024;161:156038. doi:10.1016/j.metabol.2024.156038

GHK-Cu

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108

KLOW

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
  2. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533
  3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
  5. Elliott RJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122(4):1010-1019. doi:10.1111/j.0022-202X.2004.22404.x

Lemon Bottle

  1. Humphrey S, Sykes J, Kantor J, et al. ATX-101 for reduction of submental fat: A phase III randomized controlled trial (REFINE-2). J Am Acad Dermatol. 2016;75(4):788-797.e7. doi:10.1016/j.jaad.2016.04.028
  2. Rzany B, Griffiths T, Walker P, et al. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol. 2014;170(2):445-453. doi:10.1111/bjd.12695
  3. Schuller-Petrovic S, Wölkart G, Höfler G, et al. Tissue-toxic effects of phosphatidylcholine/deoxycholate after subcutaneous injection for fat dissolution in rats and a human volunteer. Dermatol Surg. 2008;34(4):529-542. doi:10.1111/j.1524-4725.2008.34128.x
  4. Hoffmann K. Injektionslipolyse [Injection lipolysis]. Hautarzt. 2010;61(10):847-855. doi:10.1007/s00105-010-1984-x
  5. Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203. doi:10.1155/2012/976203
  6. Bylka W, Znajdek-Awiżeń P, Studzińska-Sroka E, et al. Centella asiatica in dermatology: an overview. Phytother Res. 2014;28(8):1117-1124. doi:10.1002/ptr.5110
  7. Lee H, Bae S, Kim K, et al. Beta-Catenin mediates the anti-adipogenic effect of baicalin. Biochem Biophys Res Commun. 2010;398(4):741-746. doi:10.1016/j.bbrc.2010.07.015

Η λίστα συστατικών είναι του κατασκευαστή. Οι μελέτες αφορούν την κατηγορία της ενέσιμης λιποδιάλυσης και τα επιμέρους συστατικά — όχι το ίδιο το Lemon Bottle, για το οποίο δεν υπάρχει δημοσιευμένη κλινική μελέτη.

Tesamorelin / CJC-1295 No DAC / Ipamorelin

  1. Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. doi:10.1097/QAD.0b013e32830a5058
  2. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. doi:10.1016/S2352-3018(19)30338-8
  3. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
  4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

Και ένα χωρίς μελέτες

Δεν έχει δημοσιευμένες μελέτες πίσω του: BAC Water. Γι' αυτό στη σελίδα του δεν θα βρεις ούτε ένα ποσοστό — ούτε θα σου το κρύψουμε.